Virios Therapeutics, Inc.

  • About Virios
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Corporate Presentation
  • Target Diseases
    • Fibromyalgia
    • Long Covid
    • Blog
  • Pipeline
    • Pipeline
    • Presentations and Publications
  • Investors
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
    • Shareholder Letters
    • Meeting
  • Governance
    • Overview
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • IR Contacts
    • FAQ
    • Email Alerts
  • News

  • Press Releases
  • Email Alerts
Aug 16, 2021 7:05am EDT

Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview

Aug 12, 2021 7:05am EDT

Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Aug 11, 2021 7:05am EDT

Virios Therapeutics to Present at the SNN Network Summer Virtual Conference

Aug 09, 2021 7:05am EDT

Virios Therapeutics Featured in Bloomberg TV Interview

Aug 05, 2021 7:05am EDT

Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021

Jul 26, 2021 7:05am EDT

Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1

Jun 09, 2021 7:05am EDT

Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress

Jun 04, 2021 7:05am EDT

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

Jun 02, 2021 7:05am EDT

Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology

May 24, 2021 7:05am EDT

Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

© 2023 Virios Therapeutics, Inc.           Terms and Conditions Privacy Policy Social Media Guidelines